Sunil Badve

Emory University

Full Professor(heuristic)

Breast Cancer Treatment Studies · Cancer Research

Compare more Cancer Research professors.

h-index84
i10-index259
Publications687
Citations42,676

Grants

6 total · 3 active

NIH #R33CA309789

In Vitro Human INtraDuctal (HIND) Model of Early Stage Breast Cancer Progression Heterogeneity

Active
Amount
$300K–$400K
Period
2026-05-012029-04-30
PIs
3

Awarded at GEORGIA INSTITUTE OF TECHNOLOGY

NIH #R01CA281932

Early prediction of lethal phenotypes in triple negative breast cancer using multiscale, multi-modality platforms

Active
Amount
$600K–$700K
Period
2024-04-012029-03-31
PIs
2

NIH #R33CA297922

A Novel Multi-analyte Approach to Democratize Cancer Biobanking

Active
Amount
$400K–$500K
Period
2025-04-012028-03-31
PIs
3

Awarded at GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC

Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →

All Grants

6 total · 3 active

NIH #R33CA309789

In Vitro Human INtraDuctal (HIND) Model of Early Stage Breast Cancer Progression Heterogeneity

Active
Amount
$300K–$400K
Period
2026-05-012029-04-30
PIs
3

Awarded at GEORGIA INSTITUTE OF TECHNOLOGY

NIH #R01CA281932

Early prediction of lethal phenotypes in triple negative breast cancer using multiscale, multi-modality platforms

Active
Amount
$600K–$700K
Period
2024-04-012029-03-31
PIs
2

NIH #R33CA297922

A Novel Multi-analyte Approach to Democratize Cancer Biobanking

Active
Amount
$400K–$500K
Period
2025-04-012028-03-31
PIs
3

Awarded at GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC

NIH #R01CA194600

(PQC3) Ethnicity-determined immune response and DCIS outcome

Amount
$700K–$800K
Period
2015-08-042019-07-31
PIs
2

Awarded at INDIANA UNIVERSITY INDIANAPOLIS

NIH #R21CA195152

Computerized morphologic-molecular predictor of progression in DCIS

Amount
$200K–$300K
Period
2015-04-012018-03-31
PIs
2

Awarded at CASE WESTERN RESERVE UNIVERSITY

NIH #R41CA174035

Evaluation of In Vitro Companion Diagnostic Monoclonal Antibodies for Use in a St

Amount
$200K–$300K
Period
2012-09-252014-03-31
PIs
2

Awarded at INTICA BIOMEDICAL, INC.

Recent Public Signals

  1. New paper: Data from Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation2026-06-15
  2. New NIH award: In Vitro Human INtraDuctal (HIND) Model of Early Stage Breast Cancer Progression Heterogeneity2026-05-01
  3. New preprint: Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast Cancer2025-11-10

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

Data Freshness

  • Publications as of 2026-07-09
  • Grants as of 2026-08-29

Data may not be current

Find elsewhere

ORCID: 0000-0001-8861-9980

Professor Insights

Career Trajectory